-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ML188
Category | SARS-CoV |
CAS | 1417700-13-0 |
Description | ML188 is a non-covalent SARS-CoV 3CLpro inhibitor with IC50 of 1.5 μM. |
Product Information
Synonyms | (R)-N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide |
IUPAC Name | N-[(1R)-2-(tert-butylamino)-2-oxo-1-pyridin-3-ylethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide |
Molecular Weight | 433.54 |
Molecular Formula | C26H31N3O3 |
Canonical SMILES | CC(C)(C)C1=CC=C(C=C1)N(C(C2=CN=CC=C2)C(=O)NC(C)(C)C)C(=O)C3=CC=CO3 |
InChI | InChI=1S/C26H31N3O3/c1-25(2,3)19-11-13-20(14-12-19)29(24(31)21-10-8-16-32-21)22(18-9-7-15-27-17-18)23(30)28-26(4,5)6/h7-17,22H,1-6H3,(H,28,30)/t22-/m1/s1 |
InChIKey | JXGIYKRRPGCLFV-JOCHJYFZSA-N |
Purity | 98.35% |
Solubility | In vitro: 10 mM in DMSO |
Appearance | White to off-white (Solid) |
Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
Complexity | 644 |
Exact Mass | 433.23654186 |
In Vitro | ML188 (0-30 μM; 48 hours) effectively inhibit SARS-CoV replication in cell culture. Probe ML188 is a modest molecular weight SARS-CoV 3CLpro inhibitor with demonstrated antiviral activity and a non- covalent mechanism of action. ML188 yields an antiviral EC50 value ranging from 12.9 to 13.4 μM in mock-infected and SARS- CoV infected cells. Cell Viability Assay Cell Line: Vero E6 cells (mock-infected or infected with SARS-CoV) Concentration: 3, 4, 5, 8,10, 15, 20, 30 Incubation Time: 48 hour Result: Against mock-infected and SARS-CoV infected cells |
In Vivo | ML188 (0-30 μM; 48 hours) effectively inhibit SARS-CoV replication in cell culture. |
Target | SARS-CoV; Virus Protease |
XLogP3-AA | 5 |